Market Overview
The UK Biotechnology Market was valued at USD 22.00 Billion in 2024 and is projected to reach USD 41.47 Billion by 2033, growing at a CAGR of 7.22% during 2025-2033. Growth is driven by rising chronic disease incidence, technological advances in genomics and gene editing, strong government support, and expanding applications in agriculture that improve yields and efficiency.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
UK Biotechnology Market Key Takeaways
- The UK biotechnology market size was USD 22.00 Billion in 2024.
- A CAGR of 7.22% is expected from 2025 to 2033.
- The market is forecasted to reach USD 41.47 Billion by 2033.
- Government-backed initiatives like Life Sciences Vision 2030 and R&D tax incentives support industry growth.
- Rising demand for personalized medicine and genomics is a key market driver.
- The NHS Genomic Medicine Service processed over 810,000 genomic tests in 2024, up 8% from prior year.
- Increasing applications in agriculture, including development of genetically modified crops, enhance crop yields and sustainability.
Sample Request Link:
https://www.imarcgroup.com/uk-biotechnology-market/requestsample
Market Growth Factors
Notably, the UK biotechnology industry receives strong government support, with publicly funded groups such as UK Research and Innovation (UKRI) and Innovate UK offering funding․ This allows the company to operate on a budget of £1․1 billion per year, working with over 450,000 businesses per year․ For every £1 funding of Innovate UK, £3․61 of further funding is raised from the private sector․ Incentives include the Life Sciences Vision 2030, R&D tax credits, science parks and university-business collaborations․ These encourage private companies to engage in biopharma/medtech by developing market-ready therapies in genomics, personalized medicine and synthetic biology․
Increased demand for individualized treatment and the use of genomics, with progress in genome sequencing, bioinformatics, and data analysis, have driven the adoption of genomics in treatment․ The NHS Genomic Medicine Service performed over 810,000 genomic tests in 2024, an increase of 8% on the previous year․ The United Kingdom is a world leader in precision medicine due to initiatives like the 100,000 Genomes Project․ Increased development in the field has resulted in investment in biotech companies, including those involved in cell and gene therapies, rare diseases, and molecular diagnostics, to treat complex molecular and genetic diseases․
Rising demand for sustainable agriculture is also a market driver, because resource depletion and climate change are creating demand for farm products made with sustainable farming practices․ Examples of biotechnology products are pest and climate resistant GM crops needing fewer chemical pesticides and fertilizers, and sustainable soil and water use․ Public acceptance is in favor of gene editing, with 69% of British adults supporting the use of the new technology to secure a sustainable future․ Used alongside bioinformatics, genomics, bio-based fertilizers, biopesticides and biostimulants, the techniques could be used to breed crops with better nutritional profiles or growth characteristics, along with environmentally sustainable practices that improve soil quality and water pollution․
Market Segmentation
By Product Type:
- Instruments
- Reagents: Account for the largest 45.8% market share. Used widely in drug discovery, diagnostics, genomics, proteomics, and research for enabling accurate biochemical reactions and molecular biology experiments. Demand is fueled by personalized medicine and genetic testing advancements.
- Software and Services
By Technology:
- Nanobiotechnology
- Tissue Engineering and Regeneration
- DNA Sequencing: Largest segment with a 36.8% market share. Critical for genomics, personalized medicine, and molecular diagnostics. Next-generation sequencing (NGS) advancements support projects like 100,000 Genomes Project and applications in disease gene identification and drug development.
- Cell-Based Assays
- Fermentation
- PCR Technology
- Chromatography
- Others
By Application:
- Healthcare: Dominates market with 49.6% share due to rising chronic and genetic diseases. Biotechnology is extensively applied in drug discovery, gene therapy, personalized medicine, and molecular diagnostics for conditions like cancer, cardiovascular diseases, and rare genetic disorders.
- Food and Agriculture
- Natural Resources and Environment
- Industrial Processing
- Bioinformatics
- Others
Regional Insights
London leads the UK biotechnology market, leveraging world-class research universities, advanced healthcare infrastructure, and a dense cluster of biotech startups and incubators. The region’s innovation is supported by strong government funding, private investments, and skilled talent availability, driving breakthroughs in genomics, diagnostics, and personalized medicine. South East benefits from proximity to London with numerous science parks and an active startup ecosystem enhancing collaborations in drug discovery and regenerative medicine. Other regions like North West, East of England, South West, Scotland, West Midlands, Yorkshire and The Humber, East Midlands, and others contribute through specialized sectors including bioprocessing, agricultural biotech, and precision medicine.
Recent Developments & News
In March 2025, Celex Oncology introduced a novel metastatic cancer treatment using VGSC inhibitors and monoclonal antibodies, aiming to manage cancer effectively. February 2025 saw Biocon Ltd gain MHRA approval for Liraglutide in the UK for diabetes and obesity, marking the first generic approval of its kind. Also in February, Sortera Bio spun out from MRC Laboratory of Molecular Biology with an AI-powered Deep Screening platform accelerating therapeutic discovery. Tropic prepared to launch non-browning and extended shelf-life bananas via CRISPR by year-end, securing USD 80 million in funding. In January 2025, Verdiva Bio secured USD 411 Million in Series A funding to advance obesity and cardiometabolic therapies.
Competitive Landscape
The competitive environment is highly dynamic, featuring established firms, startups, research organizations, and academic partnerships. Competition centers around next-generation therapeutics, precision medicine, genomics, and synthetic biology using advanced technologies like CRISPR gene editing and AI-based drug discovery. Frequent strategic alliances, mergers, and acquisitions broaden technological and geographic reach, supported by government-funded innovation centers and world-class research facilities.
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Customization Note
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request For Customization:
https://www.imarcgroup.com/request?type=report&id=24913&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
